Entrada Therapeutics appoints Chapman to its board of directors

Entrada Therapeutics announced the appointment of Gina Chapman to its Board of Directors, effective September 1, 2023. Ms. Chapman currently serves as President and Chief Executive Officer of CARGO Therapeutics. As President and CEO of CARGO Therapeutics, Chapman is leading the company’s development of next-generation CAR T-cell therapies that address multiple mechanisms of resistance to deliver therapies to people living with cancer. Chapman joined CARGO in May of 2022